{"id":"inoculation-in-upper-arm-deltoid","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3896316","moleculeType":"Small molecule","molecularWeight":"654.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine is injected into the deltoid muscle of the upper arm, where it triggers both humoral (antibody) and cellular immune responses. The specific mechanism depends on the vaccine type (inactivated, live attenuated, mRNA, protein subunit, etc.), but generally involves presentation of antigens to immune cells to generate protective immunity against the target disease.","oneSentence":"An inoculation administered intramuscularly in the deltoid muscle that delivers a vaccine antigen to stimulate immune response against a specific pathogen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:49:06.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Disease prevention (specific indication unknown without vaccine type specification)"}]},"trialDetails":[{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310},{"nctId":"NCT06844500","phase":"PHASE3","title":"Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-06-23","conditions":"Neonate, Maternal Transmission, Mpox","enrollment":359},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT07373301","phase":"PHASE2","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","status":"NOT_YET_RECRUITING","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2026-01-19","conditions":"Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention","enrollment":72},{"nctId":"NCT06100913","phase":"PHASE2","title":"Immunology of Ebola Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2024-08-06","conditions":"Ebola Virus Disease","enrollment":30},{"nctId":"NCT05262010","phase":"PHASE3","title":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","status":"RECRUITING","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-06-04","conditions":"HPV InfectioN, HPV-Related Carcinoma","enrollment":13500},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT07275645","phase":"PHASE3","title":"A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years","status":"NOT_YET_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-12-18","conditions":"Rabies","enrollment":3000},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":""},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT06756269","phase":"PHASE2","title":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2025-01-15","conditions":"HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia","enrollment":330},{"nctId":"NCT04919239","phase":"PHASE2","title":"Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2021-09-22","conditions":"Tuberculosis, Pulmonary","enrollment":140},{"nctId":"NCT06320535","phase":"PHASE1","title":"A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-03-25","conditions":"Malaria,Falciparum","enrollment":36},{"nctId":"NCT05477524","phase":"PHASE3","title":"An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-04","conditions":"Lyme Disease","enrollment":12547},{"nctId":"NCT04886596","phase":"PHASE3","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-25","conditions":"Respiratory Syncytial Virus Infections","enrollment":26675},{"nctId":"NCT05716347","phase":"EARLY_PHASE1","title":"Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2022-07-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT05701904","phase":"NA","title":"Vibration and Shotblocker Use in Pregnant Women While Giving Tetanus + Diphtheria Vaccine","status":"COMPLETED","sponsor":"Hasan Kalyoncu University","startDate":"2023-02-20","conditions":"Pain","enrollment":96},{"nctId":"NCT06067555","phase":"EARLY_PHASE1","title":"Intradermal Influenza Vaccination","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-01-24","conditions":"Vaccine Reaction","enrollment":249},{"nctId":"NCT05284097","phase":"PHASE2","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-09-19","conditions":"Virus Diseases, Hemorrhagic Fever, Ebola, Infections","enrollment":133},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT06731374","phase":"PHASE4","title":"Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-24","conditions":"Pneumococcal Disease, Pneumococcal Carriage","enrollment":106},{"nctId":"NCT06825312","phase":"PHASE4","title":"Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2023-11-11","conditions":"Japanese Encephalitis Vaccine","enrollment":600},{"nctId":"NCT06633835","phase":"PHASE4","title":"Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-09-20","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":660},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT06454175","phase":"PHASE1","title":"A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2024-08-03","conditions":"HPV Infection, HPV-Related Carcinoma, Genital Wart","enrollment":72},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":"Pneumococcal Infectious Disease","enrollment":240},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Gonorrhoea","enrollment":52},{"nctId":"NCT05299359","phase":"PHASE3","title":"A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-04-15","conditions":"Coronavirus Disease (COVID-19)","enrollment":150},{"nctId":"NCT04681833","phase":"PHASE2","title":"Safety and Efficacy of BARS13 in the Elderly","status":"COMPLETED","sponsor":"Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.","startDate":"2021-05-24","conditions":"Respiratory Syncytial Virus Infections","enrollment":125},{"nctId":"NCT04327206","phase":"PHASE3","title":"BCG Vaccination to Protect Healthcare Workers Against COVID-19","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2020-03-30","conditions":"Coronavirus Disease 2019 (COVID-19), Respiratory Illness, Corona Virus Infection","enrollment":6828},{"nctId":"NCT05636319","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine","status":"UNKNOWN","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2022-11-23","conditions":"COVID-19","enrollment":14168},{"nctId":"NCT02545517","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Virus Diseases, Rabies","enrollment":459},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT04652102","phase":"PHASE2, PHASE3","title":"A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-12-11","conditions":"Covid19, SARS-CoV-2","enrollment":39680},{"nctId":"NCT05027776","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2021-09-15","conditions":"HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer","enrollment":1348},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT04283461","phase":"PHASE1","title":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-16","conditions":"COVID-19, COVID-19 Immunisation","enrollment":120},{"nctId":"NCT04785144","phase":"PHASE1","title":"Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-31","conditions":"COVID-19, COVID-19 Immunisation","enrollment":135},{"nctId":"NCT03629886","phase":"PHASE4","title":"Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-22","conditions":"Cervical Intraepithelial Neoplasia","enrollment":6051},{"nctId":"NCT06312228","phase":"NA","title":"The Effect of the Helper Skin Tap Technique and Buzzy® During Vaccination","status":"COMPLETED","sponsor":"Tarsus University","startDate":"2023-05-01","conditions":"Child, Only","enrollment":96},{"nctId":"NCT05480462","phase":"PHASE3","title":"Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.","status":"UNKNOWN","sponsor":"IBSS Biomed S.A.","startDate":"2022-12-12","conditions":"Diphtheria, Tetanus","enrollment":200},{"nctId":"NCT06207175","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine","status":"UNKNOWN","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2023-11-21","conditions":"Human Papillomavirus Infection","enrollment":1260},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT05939648","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-10-09","conditions":"SARS-CoV-2","enrollment":450},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT05541952","phase":"PHASE4","title":"BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population","status":"WITHDRAWN","sponsor":"Federal University of Mato Grosso","startDate":"2020-08-17","conditions":"Latent Tuberculosis","enrollment":""},{"nctId":"NCT05683600","phase":"PHASE3","title":"Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older","status":"TERMINATED","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-29","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT05664932","phase":"PHASE3","title":"Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-28","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT06043388","phase":"PHASE1","title":"Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-09","conditions":"COVID-19","enrollment":100},{"nctId":"NCT06041061","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2023-08-13","conditions":"HPV InfectioN, HPV-Related Carcinoma","enrollment":18000},{"nctId":"NCT05205096","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT06025812","phase":"NA","title":"Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-09-20","conditions":"Coronavirus","enrollment":160},{"nctId":"NCT05198063","phase":"PHASE1, PHASE2","title":"ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-01-10","conditions":"Prevention of COVID-19","enrollment":300},{"nctId":"NCT05895110","phase":"NA","title":"To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-29","conditions":"COVID-19","enrollment":240},{"nctId":"NCT05890521","phase":"PHASE4","title":"Safety Study of COVID19 Vaccine on the Market","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-02","conditions":"COVID-19","enrollment":100000},{"nctId":"NCT05096845","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-08-25","conditions":"COVID-19 Pandemic","enrollment":22500},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT05761340","phase":"NA","title":"The Effect of Helfer Skin Tap Technique During Tetanus Injection in Pregnant Women","status":"COMPLETED","sponsor":"Celal Bayar University","startDate":"2021-08-30","conditions":"Intramuscular Injection, Pain","enrollment":65},{"nctId":"NCT05433194","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)","status":"UNKNOWN","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2022-08-22","conditions":"COVID-19","enrollment":48},{"nctId":"NCT05301504","phase":"PHASE1","title":"A Study in Tanzania of a New Vaccine Against Two Types of Ebola","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2022-03-30","conditions":"Ebola","enrollment":76},{"nctId":"NCT05033847","phase":"PHASE2","title":"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-09-12","conditions":"COVID-19 Pneumonia, Coronavirus Infections","enrollment":1800},{"nctId":"NCT05293548","phase":"PHASE2","title":"A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)","status":"UNKNOWN","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-05-25","conditions":"COVID-19","enrollment":516},{"nctId":"NCT05069129","phase":"PHASE1, PHASE2","title":"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-10-14","conditions":"COVID-19 Pneumonia, Coronavirus Infections","enrollment":1848},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05305300","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2021-10-18","conditions":"COVID-19 Pandemic","enrollment":135},{"nctId":"NCT05658614","phase":"PHASE2","title":"Anti-Schistosomiasis Sm14-vaccine in Senegal","status":"UNKNOWN","sponsor":"Oswaldo Cruz Foundation","startDate":"2022-07-01","conditions":"Schistosomiasis Mansoni, Schistosomiasis Haematobium, Vaccination; Infection","enrollment":120},{"nctId":"NCT01914367","phase":"PHASE4","title":"Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2013-06-25","conditions":"Infection With Human Papillomavirus","enrollment":12},{"nctId":"NCT05198102","phase":"PHASE1, PHASE2","title":"ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-12-29","conditions":"Prevention of COVID-19","enrollment":300},{"nctId":"NCT05124340","phase":"PHASE2","title":"Safety and Tuberculin Conversion Following BCG Vaccination","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2021-12-01","conditions":"BCG Vaccination Reaction","enrollment":220},{"nctId":"NCT02711735","phase":"PHASE2","title":"Safety of RUTI® Vaccination in MDR-TB Patients","status":"TERMINATED","sponsor":"Archivel Farma S.L.","startDate":"2020-03-18","conditions":"Tuberculosis, Multidrug Resistant","enrollment":9},{"nctId":"NCT04553016","phase":"PHASE1","title":"A Study to Test Three Experimental HIV Vaccines in Healthy Adults.","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-08-16","conditions":"HIV-1-infection","enrollment":88},{"nctId":"NCT05289206","phase":"NA","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-30","conditions":"Comorbidities and Coexisting Conditions, Healthy","enrollment":4446},{"nctId":"NCT05128643","phase":"PHASE3","title":"Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-17","conditions":"Coronavirus Disease 2019","enrollment":300},{"nctId":"NCT02504203","phase":"PHASE4","title":"Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial","status":"TERMINATED","sponsor":"Bandim Health Project","startDate":"2015-11","conditions":"Infant Mortality, BCG","enrollment":2332},{"nctId":"NCT05205083","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV","status":"UNKNOWN","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05193734","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2022-02-07","conditions":"Pertussis, Vaccine-Preventable Diseases","enrollment":100},{"nctId":"NCT04560881","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2020-09-16","conditions":"COVID-19 Virus Infection","enrollment":3000},{"nctId":"NCT05157230","phase":"NA","title":"Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination","status":"COMPLETED","sponsor":"Bursa Yuksek Ihtisas Training and Research Hospital","startDate":"2021-09-01","conditions":"Vaccines, Adverse Effects, Injection Site Reaction","enrollment":401},{"nctId":"NCT04083196","phase":"PHASE1","title":"A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2019-09-07","conditions":"HPV Infection, HPV-Related Cervical Carcinoma","enrollment":90},{"nctId":"NCT05089045","phase":"NA","title":"Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-08-31","conditions":"Coronavirus Disease 2019","enrollment":360},{"nctId":"NCT05017792","phase":"PHASE3","title":"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt","status":"UNKNOWN","sponsor":"Samia Hassan El-Shishtawy","startDate":"2021-08-30","conditions":"Covid19","enrollment":200},{"nctId":"NCT03443427","phase":"PHASE2","title":"A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-20","conditions":"Respiratory Disorders","enrollment":200},{"nctId":"NCT05003466","phase":"PHASE2","title":"Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)","status":"UNKNOWN","sponsor":"Shenzhen Kangtai Biological Products Co., LTD","startDate":"2021-09","conditions":"COVID-19","enrollment":480},{"nctId":"NCT04990648","phase":"NA","title":"Buzzy® Application in Pain","status":"COMPLETED","sponsor":"Okan University","startDate":"2018-11-15","conditions":"Healthy","enrollment":60},{"nctId":"NCT00488592","phase":"PHASE2","title":"Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2007-06","conditions":"Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":10},{"nctId":"NCT01798056","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-06","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Inoculation in upper arm deltoid","genericName":"Inoculation in upper arm deltoid","companyName":"Beijing Center for Disease Control and Prevention","companyId":"beijing-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"An inoculation administered intramuscularly in the deltoid muscle that delivers a vaccine antigen to stimulate immune response against a specific pathogen. Used for Disease prevention (specific indication unknown without vaccine type specification).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}